167 related articles for article (PubMed ID: 30129449)
1. Biosimilars for insulin: a cost-saving alternative?
McCall C
Lancet; 2018 Aug; 392(10146):463-464. PubMed ID: 30129449
[No Abstract] [Full Text] [Related]
2. Biosimilar insulin could offer patients cost-saving options.
Karlovitch S
Am J Manag Care; 2019 Sep; 25(10 Spec No.):. PubMed ID: 31860243
[No Abstract] [Full Text] [Related]
3. The impact of biosimilar insulins on the diabetes landscape.
White J; Wagner A; Patel H
J Manag Care Spec Pharm; 2022 Jan; 28(1):91-98. PubMed ID: 34726499
[TBL] [Abstract][Full Text] [Related]
4. Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018).
Agirrezabal I; Sánchez-Iriso E; Mandar K; Cabasés JM
Diabetes Care; 2020 Aug; 43(8):1767-1773. PubMed ID: 32527798
[TBL] [Abstract][Full Text] [Related]
5. Biosimilar insulin and insulin antibodies.
Heinemann L; Owens D
J Diabetes Sci Technol; 2013 Jul; 7(4):806-7. PubMed ID: 23911160
[No Abstract] [Full Text] [Related]
6. New Insulins, Biosimilars, and Insulin Therapy.
Danne T; Heinemann L; Bolinder J
Diabetes Technol Ther; 2016 Feb; 18 Suppl 1():S43-55. PubMed ID: 26836429
[No Abstract] [Full Text] [Related]
7. The rise of biosimilars in cancer care.
Roe H
Br J Nurs; 2015 Feb 26-Mar 11; 24(4):S28-9. PubMed ID: 25723369
[No Abstract] [Full Text] [Related]
8. [Biosimilars - Potential, risks and open questions].
Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883
[No Abstract] [Full Text] [Related]
9. Biosimilars for Management of Crohn Disease.
Nielsen OH; Ainsworth MA
Ann Intern Med; 2019 Jan; 170(2):129-130. PubMed ID: 30535358
[No Abstract] [Full Text] [Related]
10. A long war begins: biosimilars versus patented biologics.
Bocquet F; Paubel P
J Med Econ; 2015; 18(12):1071-3. PubMed ID: 26212478
[No Abstract] [Full Text] [Related]
11. Addressing Insulin Access and Affordability: An Endocrine Society Position Statement.
Endocrine Society
J Clin Endocrinol Metab; 2021 Mar; 106(4):935-941. PubMed ID: 33433590
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar Insulin and Costs: What Can We Expect?
Heinemann L
J Diabetes Sci Technol; 2015 Sep; 10(2):457-62. PubMed ID: 26350722
[TBL] [Abstract][Full Text] [Related]
13. The advent of biosimilars for the treatment of diabetes: current status and future directions.
Polimeni G; Trifirò G; Ingrasciotta Y; Caputi AP
Acta Diabetol; 2015 Jun; 52(3):423-31. PubMed ID: 25990669
[TBL] [Abstract][Full Text] [Related]
14. Greater potential cost savings with biosimilar use.
Yu B
Am J Manag Care; 2016 May; 22(5):378. PubMed ID: 27266439
[No Abstract] [Full Text] [Related]
15. Examining the Causes and Consequences of Increasing Insulin Costs With Prospective Interventions.
Dawkins M; Menon T; Myers AK
Am J Ther; 2020; 27(1):e115-e120. PubMed ID: 31703009
[No Abstract] [Full Text] [Related]
16. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
Grabowski HG; Guha R; Salgado M
Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
[TBL] [Abstract][Full Text] [Related]
17. Path of Interchangeability of Biosimilars in Pediatric Inflammatory Bowel Disease: Quality Before Cost Savings.
Patel D; Park KT
J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):134-136. PubMed ID: 28319603
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar products are not bioidentical.
Garber AJ
J Diabetes; 2015 Mar; 7(2):153-4. PubMed ID: 25395269
[No Abstract] [Full Text] [Related]
19. [Without short acting insulin analogs. Is therapy quality really maintained? (interview by Dirk Einecke)].
Lüddeke HJ
MMW Fortschr Med; 2006 Sep; 148(37):9. PubMed ID: 17036893
[No Abstract] [Full Text] [Related]
20. [Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].
Berreur B; Guerin F; Christophe B; Limido G; Paubel P
Ann Pharm Fr; 2018 Jan; 76(1):57-63. PubMed ID: 29180236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
